Skip to main content
Back
BSX logo

Boston Scientific Corporation

Data quality: 100%
BSX
NYSE Healthcare Medical - Devices
$69.54
▲ $0.06 (0.09%)
Mkt Cap: 103.19B
Day Range
$68.85 $70.50
52-Week Range
$67.56 $109.50
Volume
8,603,601
50D / 200D Avg
$80.41 / $95.75
Prev Close
$69.48

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 35.8 0.4
P/B 4.3 2.9
ROE % 12.6 3.8
Net Margin % 14.4 3.9
Rev Growth 5Y % 14.0 10.0
D/E 0.5 0.2

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Mar 2, 2026
Morano Susan E
Director
grant 24
Mar 2, 2026
Pegus Cheryl
Director
grant 24
Mar 1, 2026
Woodworth Emily
SVP, Global Controller and CAO
other 2,048
Nov 28, 2025
O'Sullivan Miriam
SVP, Chief HR Officer
other 260
Nov 14, 2025
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
other 9,610
Nov 12, 2025
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
other 690
Aug 1, 2025
LUDWIG EDWARD J
Director
other 500
Jul 29, 2025
FUJIMORI YOSHIAKI
Director
sell 2,901 $106.99 $310,378
Jul 1, 2025
Monson Jonathan
EVP and CFO
grant 30,523
May 29, 2025
LUDWIG EDWARD J
Director
sell 4,000 $104.59 $418,368
May 21, 2025
Brown Vance R
SVP, GC and Corp. Secretary
sell 4,826 $106.42 $513,583
May 8, 2025
Habiger David C
Director
grant 2,081
May 8, 2025
WICHMANN DAVID S
Director
grant 2,081
May 8, 2025
Mega Jessica L
Director
grant 2,081
May 8, 2025
Zane Ellen M
Director
grant 2,081
May 8, 2025
LUDWIG EDWARD J
Director
grant 2,081
May 5, 2025
Sorenson John Bradley
EVP, Global Operations
sell 4,572 $104.54 $477,957
May 2, 2025
Sorenson John Bradley
EVP, Global Operations
other 10,326
May 2, 2025
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
other 5,221
Apr 21, 2025
Brown Vance R
SVP, GC and Corp. Secretary
sell 4,826 $95.09 $458,904

Key Takeaways

Revenue grew 13.99% annually over 5 years — strong growth
Earnings grew 55.66% over the past year
ROE of 12.55% — decent returns on equity
Generating 3.66B in free cash flow
P/E of 35.76 — premium valuation
PEG of 0.88 suggests growth is underpriced

Growth

Revenue Growth (5Y)
13.99%
Revenue (1Y)19.87%
Earnings (1Y)55.66%
FCF Growth (3Y)46.56%

Quality

Return on Equity
12.55%
ROIC8.13%
Net Margin14.38%
Op. Margin19.78%

Safety

Debt / Equity
0.51
Current Ratio1.62
Interest Coverage11.38

Valuation

P/E Ratio
35.76
P/B Ratio4.26
EV/EBITDA28.60
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19.87% Revenue Growth (3Y) 18.73%
Earnings Growth (1Y) 55.66% Earnings Growth (3Y) 34.60%
Revenue Growth (5Y) 13.99% Earnings Growth (5Y) 29.07%
Profitability
Revenue (TTM) 20.07B Net Income (TTM) 2.89B
ROE 12.55% ROA 6.61%
Gross Margin 69.01% Operating Margin 19.78%
Net Margin 14.38% Free Cash Flow (TTM) 3.66B
ROIC 8.13% FCF Growth (3Y) 46.56%
Safety
Debt / Equity 0.51 Current Ratio 1.62
Interest Coverage 11.38 Dividend Yield 0.00%
Valuation
P/E Ratio 35.76 P/B Ratio 4.26
P/S Ratio 5.14 PEG Ratio 0.88
EV/EBITDA 28.60 Dividend Yield 0.00%
Market Cap 103.19B Enterprise Value 113.56B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 20.07B 16.75B 14.24B 12.68B 11.89B
Net Income 2.89B 1.85B 1.59B 698.00M 1.04B
EPS (Diluted) 1.94 1.25 1.07 0.45 0.69
Gross Profit 13.85B 10.27B 8.83B 7.71B 7.46B
Operating Income 3.97B 2.64B 2.18B 1.82B 1.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 43.67B 39.40B 35.14B 32.47B 32.23B
Total Liabilities 19.20B 17.39B 15.61B 14.90B 15.61B
Shareholders' Equity 24.23B 21.77B 19.28B 17.57B 16.62B
Total Debt 12.42B 11.15B 9.49B 9.28B 9.45B
Cash & Equivalents 2.05B 414.00M 865.00M 928.00M 1.93B
Current Assets 8.79B 6.92B 6.51B 5.76B 6.32B
Current Liabilities 5.44B 6.40B 4.93B 3.80B 4.27B

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#521 of 1024
45

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026